<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03955809</url>
  </required_header>
  <id_info>
    <org_study_id>osagir3</org_study_id>
    <nct_id>NCT03955809</nct_id>
  </id_info>
  <brief_title>Comparison the Effects of 3 Different Intraarticular Ketamine Doses on Postoperative Pain.</brief_title>
  <official_title>Effects of İntraarticular and Periarticular Applied Drugs on Postoperative Pain Management in Artroscopic Knee Surgery for</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Balikesir University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Balikesir University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      the aim is to compare the effects of two different doses of intraarticular ketamine on
      postoperative pain scores and analgesic requirements.in knee artroscopy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All pateints are going to be operated under general anesthesia. At the end of the study
      patients are going to be randomyl seperated into 3 groups. The surgeon is going the following
      drugs intraarticulary.

      Group KL1: 0.5 mg/kg ketamin in % 0..9 NaCl at a total volume of 20 ml Group KL2: 1 mg/kg
      ketamin in % 0.9 NaCl at a total volume of 20 ml Group SL: 20 ml % 0.9 NaCl ll patients are
      going to receive a periarticula injection of 10 ml 0.5 bupivacaine and patient controlled
      analgesia with morphine.

      VAS scores and total analgesic requirement is going to be evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in postoperative pain scores throughout time evaluated by VAS</measure>
    <time_frame>VAS scores at rest and during activity will be evaluated for 24 hours. The first measurement will be recorded immediately after surgery and at 30 minutes interval for the first hour. Afterwards at 2.4.6.12.24.hours postoperatively.</time_frame>
    <description>Pain scores are going to be evaluated by VAS scores at rest and VAS scores at activity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference in opioid Sparing effect measured through morphine amount delivered by a patient controlled analgesia device.</measure>
    <time_frame>Total amount off delivered morphine will be recorded for 24 hours.</time_frame>
    <description>The total amount of morphine delivered by the patient controlled analgesia device in the first 24 hours will be recorded.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time for discharge measured by eligible for discharge criteria</measure>
    <time_frame>Discharge criterias will be evaluated every three hours until postoperative 24. hour. In patients who did not complete the discharge criteria in the postoperative 24 hours period, they will be defined as prolonged discharge.</time_frame>
    <description>The time needed to fullfill the dicharge criteria (stable vital signs, able to walk, able to eat, nausea and vomit free, able to mixture)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Arthroscopy</condition>
  <arm_group>
    <arm_group_label>Ketamine 0.5 mg/kg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ketamin 0.5 mg/kg intraarticular</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketamine 1 mg/kg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ketamin 1 mg/kg intraarticular injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>% 0.9 Saline</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>% 0.9 NaCL intraarticular injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine 0.5</intervention_name>
    <description>İntrarticular Ketamine 0.5 mg/kg + 0.9 Nacl Total Volume 20 ml</description>
    <arm_group_label>Ketamine 0.5 mg/kg</arm_group_label>
    <other_name>Group 1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine 1</intervention_name>
    <description>İntrarticular Ketamine 1 mg/kg + 0.9 NaCl Total Volume 20 ml</description>
    <arm_group_label>Ketamine 1 mg/kg</arm_group_label>
    <other_name>Group 2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>% 0.9 NaCl</intervention_name>
    <description>Intraarticular %0.9 NaCl</description>
    <arm_group_label>% 0.9 Saline</arm_group_label>
    <other_name>Group 3</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Artroscopic surgery

          -  ASA I-II

        Exclusion Criteria:

          -  Long time NSAID use

          -  Travmatic knee injury

          -  Long ter analgesic use

          -  Intraartiular catheter insertion at the end of surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>May 14, 2019</study_first_submitted>
  <study_first_submitted_qc>May 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 20, 2019</study_first_posted>
  <last_update_submitted>January 19, 2020</last_update_submitted>
  <last_update_submitted_qc>January 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Balikesir University</investigator_affiliation>
    <investigator_full_name>Ozlem Sagir, MD</investigator_full_name>
    <investigator_title>Associated Professor</investigator_title>
  </responsible_party>
  <keyword>Injection</keyword>
  <keyword>Intra-Articular</keyword>
  <keyword>arthroscopy</keyword>
  <keyword>ketamine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

